Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.03, 8.01, 9.01 · 8-K

MITESCO INC

MITIOTCEQUITYCurrent

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 5, 2026, the Board of Directors (the “Board”) approved via unanimous written consent an amendment to the Company’s Articles of Incorporation to increase the total shares of Common Stock the Company is authorized to issue from five hundred million (500,000,000) to one billion (1,000,000,000), with a par…

Filed Nov 20, 2026Accepted Nov 20, 2026, 4:39 PM ESTCIK 802257Accession 0001185185-26-005574
Share

Company context

Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we shut down our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. In October 2023, the Company changed its domicile from Delaware to Nevada in order to effect reduced costs.

Current securities

Historical securities (7)

Recent company filings

  1. PRE 14C filingNov 20, 2026
  2. NT 10-Q filingNov 16, 2026
  3. Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other EventsNov 6, 2026
  4. Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsOct 28, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsOct 13, 2026

Disclosure sections

Items 5.03, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 5, 2026, the Board of Directors (the “Board”) approved via unanimous written consent an amendment to the Company’s Articles of Incorporation to increase the total shares of Common Stock the Company is authorized to issue from five hundred million (500,000,000) to one billion (1,000,000,000), with a par value of $0.001 per share (the “Authorized Stock Increase”), and on November 18, 2026, modified that consent to increase the authorized common stock to 20 billion (20,000,000,000). We recommended the shareholders of the Series X Preferred shares approve the Authorized Stock Increase. On November 18, 2026, shareholders holding 50.95% of Company’s voting stock, voting on as-converted basis (“Consenting Shareholders”) took this action by written consent to approve the Authorized Stock Increase. The Board of Directors has approved this action and is taking all steps necessary to implement the change. The Company will file an information statement as soon as practical informing the shareholders of the change. The Company currently has approximately 66 million shares outstanding and around 26 million shares in the float. It also is required to reserve certain shares for the potential issuance underlying its convertible debt and other commitments. It currently has over 900 million shares, 91% of its authorized shares held in this reserve. There is no transaction or event under consideration that management believes would utilize the new level of authorized shares.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. The Company continues discussions with a number of acquisition candidates and the restructuring of its Bridge notes and Series A Preferred shares. The change in the number of authorized shares of its common stock was not related to any particular transaction or event.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.